ProCE Banner Activity

Utility of Kinase Inhibitors in the Management of Relapsed CLL

Clinical Thought
Have you integrated recently approved kinase inhibitors into your management strategies for patients with relapsed CLL?

Released: April 27, 2015

Expiration: April 25, 2016

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Farrukh Awan, MD, MS, has disclosed that he has received consulting fees from Boehringer Ingelheim.